Nyxoah’s (NYXH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Nyxoah (NASDAQ:NYXH) in a research note released on Friday, Marketbeat Ratings reports. HC Wainwright currently has a $17.00 price target on the stock.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Nyxoah in a research report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Nyxoah presently has an average rating of “Buy” and a consensus price target of $17.00.

Nyxoah Stock Up 1.5 %

NYXH opened at $8.00 on Friday. The firm has a market capitalization of $199.52 million, a P/E ratio of -4.28 and a beta of 1.35. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00. The company’s 50-day moving average is $8.86 and its 200 day moving average is $8.53.

Institutional Trading of Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Kovack Advisors Inc. purchased a new stake in shares of Nyxoah S.A. (NASDAQ:NYXH) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $96,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.